The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.
MK-3475 Efficacy Expanded With Longer Follow-Up in Melanoma
November 18th 2013The investigational anti-PD-1 immunotherapy MK-3475 has demonstrated an overall survival rate of 81% at one year in patients with advanced melanoma, according to additional data from a phase Ib clinical trial presented at the 10th International Congress of the Society for Melanoma Research in Philadelphia.
IOM Issues Recommendations to Improve Cancer Care Delivery
November 15th 2013Delivering high-quality cancer care continues to be a daunting problem for the US healthcare system because of a combination of factors, including an aging population, a shrinking work force, the rising cost of therapies, and a complex disease state and treatment regimen.
Drugs and Biologics Account for Largest Practice Expenses
November 13th 2013The highest expense reported by community oncology practices continues to be attributable to drugs and biologics, according to "2013 Trends in Community Cancer Centers," a survey sponsored by the Association of Community Cancer Centers.
Everolimus Offers Benefit in Papillary Renal Cell Carcinoma
November 13th 2013Everolimus provides clinical benefit to patients with papillary metastatic renal cell carcinoma, offering promising overall survival results and a tolerable side-effect profile, investigators found in a study presented during the 2013 European Cancer Congress in Amsterdam.
How One Oncology Practice Took Advantage of Economies of Scale
November 12th 2013One oncology practice in Florida seems to have been able to adapt its practice model, taking advantage of economies of scale, and identifying new revenue streams, while still providing quality care and keeping its oncologists satisfied professionally.
FDA Approves Frontline Obinutuzumab for CLL
November 1st 2013The FDA has approved obinutuzumab plus chlorambucil as a first-line treatment for patients with chronic lymphocytic leukemia, based on clinical trial data demonstrating that the combination more than doubled median PFS over the chemotherapy agent alone.
Large-Scale Analysis Confirms Superiority of Hyperfractionation in HNSCC
October 29th 2013Hyperfractionated radiotherapy improved overall survival rates compared to standard and accelerated radiotherapy when administered without concomitant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma.
Pre-Chemo Trial of Enzalutamide Halted After Meeting Endpoints
October 22nd 2013The phase III PREVAIL trial of enzalutamide in chemotherapy-naïve patients with advanced prostate cancer has been stopped early after meeting its co-primary endpoints of overall survival and radiographic progression-free survival
Vemurafenib Demonstrates Antitumor Activity in Papillary Thyroid Cancer
October 18th 2013In a phase II clinical trial, the BRAF inhibitor vemurafenib demonstrated antitumor activity in patients with BRAFV600E-mutated papillary thyroid cancer who were either TKI treatment naïve or had received prior TKI treatments.